AIRA Matrix vs Visiopharm (2026)
AIRA Matrix and Visiopharm both sell deep learning image analysis for pathology, and they part ways on regulation and on who the work is for. Visiopharm packages its diagnostic algorithms as APPs that quantify HER2, Ki67, ER and PR and detect metastases in breast cancer, assess PD-L1 in lung cancer and analyze prostate cancer on its Insight platform. Its CE IVD APPs are certified under the EU IVDR for diagnostic use in the EU and UK, with research APPs offered in the United States. UMC Utrecht's CONFIDENT-B trial ran its metastasis APP in routine diagnosis, and since May 2026 the company has been owned by the scanner maker Grundium. AIRA Matrix, based in Thane, India, labels its products Research Use Only. On the preclinical side, AIRATox triages and quantifies findings in toxicology studies on a self supervised model trained on 130,000 whole slide images across six species, PredTox predicts organ toxicity from compound data, and AIRADHI manages GLP studies with audit trails and electronic signatures. On the clinical research side, AIRAProstate classifies Gleason patterns and AIRAQc flags slides with artifacts against thresholds a lab sets. Peer reviewed studies with Johns Hopkins, Radboud University Medical Center and LabCorp cover its models. For diagnostic use in Europe, Visiopharm's IVDR certified APPs carry the regulatory basis and a prospective trial; for preclinical toxicology and compound screening, AIRA Matrix sells tools built for that work. Both run in the cloud or on premise and are available through Sectra. Neither publishes a security attestation or a price, and Visiopharm states its processor role under the GDPR while AIRA Matrix states no HIPAA or data protection position.
- AIRATox screens, triages and quantifies findings in toxicology studies across species, on a model trained on 130,000 whole slide images from more than 40 labs.
- PredTox predicts in vivo organ toxicity from compound data on a desktop platform, keeping molecule information inside the organization.
- AIRADHI manages GLP studies with audit trails and electronic signatures for 21 CFR Part 11, in the cloud or on premise.
- AIRAQc accepts or flags each slide for rescanning against artifact thresholds the lab sets, with 95% sensitivity and 96% specificity reported.
- Prostate cancer models studied with Johns Hopkins and in a Radboud evaluation of Gleason algorithms on outside data.
- CE IVD APPs certified under the IVDR for diagnostic use in the EU and UK, across breast, lung and prostate cancer and lymph node metastasis.
- The metastasis APP was tested in routine diagnosis in UMC Utrecht's prospective CONFIDENT-B trial, published in Nature Cancer in 2024.
- APPs validated to Agilent assays and the Omnis platform are sold with Agilent as the Visiopharm Diagnostic Package.
- Runs on the web, on premises or hybrid, inside Sectra IDS7 or Proscia Concentriq AP, with analysis triggered from LIS metadata.
- Qualitopix checks IHC staining consistency, and the Grundium scanner is offered alongside the software.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AIRA Matrix and Visiopharm are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AIRA Matrix | Visiopharm |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | Not recorded | 2001 |
| Headquarters | Thane, Maharashtra, India | Hoersholm, Denmark |
| Website | airamatrix.com | visiopharm.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
AIRA Matrix, based in Thane, India, sells deep learning pathology tools labeled Research Use Only: AIRATox, PredTox and AIRADHI for preclinical toxicology and drug development, AIRAProstate for prostate cancer analysis and AIRAQc for slide quality control, in the cloud or on premise. Its algorithms are offered through Sectra, Techcyte, Gestalt and Lumea, and peer reviewed studies with Johns Hopkins, Radboud University Medical Center and LabCorp cover its models. No security attestation, HIPAA position or price is published.
Source: AI Health Index, November 2026
Visiopharm, a Danish company owned since May 2026 by the scanner maker Grundium, sells pathology image analysis APPs for breast, lung and prostate cancer and lymph node metastasis on its Insight platform, with CE IVD APPs certified under the EU IVDR and research APPs in the United States. It integrates with Sectra and Proscia, runs on the web, on premises or hybrid, and partners with Agilent on validated assays. No security attestation, data processing agreement or price is published.
Source: AI Health Index, November 2026
Questions buyers ask
How does Visiopharm compare with AIRA Matrix?
Both sell deep learning image analysis for pathology. Visiopharm sells diagnostic APPs for breast, lung and prostate cancer and metastasis detection, with CE IVD certification under the EU IVDR. AIRA Matrix labels its products Research Use Only and concentrates on preclinical toxicology and drug development, alongside prostate cancer analysis and slide quality control. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
How much do AIRA Matrix and Visiopharm cost?
Neither publishes a price. AIRA Matrix offers image analysis as a service, pay per use for small projects or by subscription, beside its software. Visiopharm also sells the Visiopharm Diagnostic Package with Agilent, validated to Agilent assays and the Omnis platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
Can AIRA Matrix or Visiopharm be used for diagnosis?
Visiopharm's CE IVD APPs are certified for diagnostic use in the EU and UK; in the United States its diagnostic APPs are not sold and research APPs are offered instead. AIRA Matrix labels its products Research Use Only and not for use in diagnostic procedures, and Sectra's marketplace lists AIRAProstate as research only. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
Which systems do AIRA Matrix and Visiopharm work with?
Visiopharm integrates with Sectra IDS7 and Proscia Concentriq AP, with analysis triggered from laboratory information system metadata and results shown in the Sectra viewer. AIRA Matrix algorithms are offered through Sectra's Amplifier marketplace, Techcyte Fusion, Gestalt PathFlow and Lumea, follow HL7 metadata standards and work with multiple scanners. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
Do AIRA Matrix and Visiopharm support preclinical research?
AIRA Matrix sells preclinical products directly: AIRATox for toxicology study slides across species, PredTox for toxicity prediction from compound data, and AIRADHI for GLP image management. Visiopharm offers translational APPs for research beside its diagnostic APPs. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified November 16, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither AIRA Matrix nor Visiopharm publishes a price, a security attestation such as SOC 2 or ISO 27001, or a document that governs patient slide images, and neither holds a US clearance.
AIRA Matrix labels every product Research Use Only while its prostate pages describe diagnosis and treatment planning. It states no HIPAA or data protection position and names no host for its cloud deployment, and its accuracy figures are given as up to values without the dataset behind them.
Visiopharm's privacy policy covers business contact data and says a data processing agreement is concluded where it processes data for a customer, with no agreement published, and nothing is published on retention or training use for slide images.